15.9 C

FDA panel rejects Pfizer arthritis drug as too risky

U.S. health advisers sharply criticized the experimental arthritis drug on Thursday, saying it was too risky, even with restrictions on its use.

The Chamber of Experts of the Food and Drug Administration confirmed by a 19-1 vote that the modest benefits of the drug do not outweigh its significant risks, even with the means offered to limit the number of people receiving medication. Pfizer is seeking FDA approval for a drug called tanezumab to treat mild arthritis of the thighs and knees. It is given by injection every two months.

A small percentage of participants in the study found that joint damage worsened more rapidly, sometimes requiring hip or knee replacement. Others had a tumor or a nerve injury. Some have damaged healthy joints.

“I’m concerned about long-term side effects,” said Dr. Lee D. Katz, an X-ray at Yale University School of Medicine, referred to the doctor’s oath to “do no harm first.”

The FDA does not have to follow the advice or advice of its outside experts, but it usually does. A detailed examination of the drug by FDA staff led to the same conclusions as the panel.

In a statement, Pfizer said it was disappointed with the vote on the drug, which has been under development for 15 years.

“We will continue to work with the FDA to determine the next steps,” said my intern, Rusnak, director general of internal medicine development.

During the two-day hearing, many experts said that tanzumab did not work better than the non-steroidal anti-inflammatory drugs commonly used for arthritis pain, such as Aleve և Celebrex. They also expressed concern that although people were likely to take medication for many years, they were only one year behind the study participants in the longest study.


Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma


The Associated Press Department of Health and Science receives support from the Department of Science Education at Howard Hughes Medical Institute. The AP is solely responsible for all content.


Please enter your comment!
Please enter your name here